10-Q quarterly report · filed Nov 4, 2026

Rapport Therapeutics, Inc. (RAPP) Q3 2026 10-Q Quarterly Report

Short answer

Rapport Therapeutics, Inc. (RAPP) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $0 with net income of −$40M.

Q3 2026 key financials · XBRL

Revenue
$0
Net income
−$40M
−49.4% YoY · +28.9% QoQ
EPS (diluted)
−$0.85
−19.7% YoY · +28.6% QoQ

Source: XBRL data from the Rapport Therapeutics, Inc. (RAPP) Q3 2026 10-Q on SEC EDGAR. USD.

Rapport Therapeutics, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly revenue: $0, consistent with no product sales; nine-month collaboration revenue $20.0M vs $0
  • Operating margin: (100.0%) vs (100.0%) YoY, net loss $40.2M vs $26.9M
  • Worst performance: RAP-219 R&D costs $17.5M, up $8.7M YoY, driven by Phase 3 development
  • Cash, equivalents and short-term investments $395.0M; operating cash use $96.1M for nine months
  • Outlook: Phase 3 FOS trials enrolling; expenses expected to increase substantially; funding projected through 2029

Risk Factors

  • Newly expanded AI/ML risk: EU AI Act and emerging U.S. state laws could impose costly governance, transparency, monitoring and human-oversight requirements
  • Most materially updated regulatory risk: FDA’s June 2026 draft guidance may permit one pivotal trial, but FDA retains discretion to require additional clinical data
  • Privacy compliance exposure: GDPR penalties can reach €20 million or 4% of annual global revenues
  • Near-term clinical risk: RAP-219 Phase 3 programs face delays from enrollment, safety, efficacy or regulatory requirements
  • Financial risk: $172.5 million of 2.25% convertible senior notes mature in 2032

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Rapport Therapeutics, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.